CINECA IRIS Institutional Research Information System

CIANCIO, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.536
EU - Europa 5.035
AS - Asia 2.694
AF - Africa 95
SA - Sud America 82
OC - Oceania 48
Continente sconosciuto - Info sul continente non disponibili 6
Totale 14.496
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.360
CN - Cina 1.690
DE - Germania 983
IT - Italia 967
IE - Irlanda 579
SE - Svezia 482
FR - Francia 353
UA - Ucraina 316
DK - Danimarca 310
GB - Regno Unito 244
FI - Finlandia 223
KR - Corea 201
IN - India 156
CA - Canada 150
AT - Austria 149
JP - Giappone 142
VN - Vietnam 124
TW - Taiwan 98
PL - Polonia 83
RU - Federazione Russa 78
ES - Italia 60
HK - Hong Kong 56
NL - Olanda 55
BR - Brasile 46
AU - Australia 45
ID - Indonesia 43
SG - Singapore 36
PK - Pakistan 31
BE - Belgio 29
RO - Romania 28
GR - Grecia 25
EG - Egitto 24
TR - Turchia 24
CH - Svizzera 22
CO - Colombia 19
MX - Messico 19
IR - Iran 18
UZ - Uzbekistan 18
KE - Kenya 16
TH - Thailandia 13
PH - Filippine 12
HR - Croazia 10
NG - Nigeria 10
PT - Portogallo 9
HU - Ungheria 7
IL - Israele 7
BF - Burkina Faso 6
EU - Europa 6
IQ - Iraq 6
SD - Sudan 6
AR - Argentina 5
CZ - Repubblica Ceca 5
ET - Etiopia 5
MN - Mongolia 5
CM - Camerun 4
NO - Norvegia 4
PE - Perù 4
TN - Tunisia 4
VE - Venezuela 4
ZA - Sudafrica 4
ZM - Zambia 4
EC - Ecuador 3
MY - Malesia 3
MZ - Mozambico 3
NZ - Nuova Zelanda 3
SA - Arabia Saudita 3
YE - Yemen 3
CR - Costa Rica 2
CU - Cuba 2
GM - Gambi 2
LV - Lettonia 2
LY - Libia 2
MD - Moldavia 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
BG - Bulgaria 1
BY - Bielorussia 1
CD - Congo 1
CI - Costa d'Avorio 1
CL - Cile 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GE - Georgia 1
HT - Haiti 1
LB - Libano 1
LT - Lituania 1
LU - Lussemburgo 1
MK - Macedonia 1
MU - Mauritius 1
MV - Maldive 1
PA - Panama 1
PS - Palestinian Territory 1
SN - Senegal 1
UG - Uganda 1
Totale 14.496
Salva come PNG Salva come JPEG
Città #
Ann Arbor 898
Chandler 784
Beijing 747
Dublin 577
Fairfield 341
Houston 319
Torino 274
Dearborn 246
Redwood City 229
Ashburn 209
Wilmington 203
Villeurbanne 199
Nyköping 191
Woodbridge 190
Medford 181
Princeton 179
Jacksonville 177
Vienna 142
Shanghai 118
Guangzhou 113
Seattle 105
Cambridge 95
Pisa 72
Warsaw 72
Dong Ket 67
Nanjing 67
Hangzhou 62
Boston 59
Toronto 55
Milan 54
Ottawa 54
Fremont 52
Taipei 51
Chengdu 49
Turin 46
New York 44
Rome 42
Wuhan 42
Boardman 39
Tokyo 36
Hefei 34
Nürnberg 31
Jakarta 28
Norwalk 27
San Diego 27
Seoul 25
Kunming 24
Zhengzhou 24
Verona 22
Singapore 21
Falls Church 20
Brussels 19
Helsinki 19
Munich 19
Changsha 18
Chongqing 18
Jinan 18
West Jordan 18
London 17
San Mateo 17
Hebei 16
Nanchang 16
Pune 16
Washington 16
Amsterdam 15
Mountain View 15
Duncan 14
Fuzhou 14
Naples 14
Rochester 14
Central 13
Central District 13
Karachi 13
Phoenix 13
Delhi 12
Gurgaon 12
Nanning 12
Barcelona 11
Lachine 11
Tianjin 11
Abuja 10
Athens 10
Bengaluru 10
Cupertino 10
Hanoi 10
Melbourne 10
Paris 10
Bologna 9
Chicago 9
Hyderabad 9
Los Angeles 9
Madrid 9
Bucharest 8
Changchun 8
Guiyang 8
Ho Chi Minh City 8
Lahore 8
Leawood 8
San Francisco 8
Xiamen 8
Totale 8.376
Salva come PNG Salva come JPEG
Nome #
Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection 940
Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma 546
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 478
Outcome of chronic delta hepatitis in Italy: a long-term cohort study. 336
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α 335
DURABILITY OF THE RESPONSE TO PEGINTERFERON ALFA2b AND RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A COHORT STUDY IN THE ROUTINE CLINICAL SETTING. 311
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II 294
The prenylation inhibitor, lonafarnib: A new therapeutic strategy against hepatitis delta 282
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 273
Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents 270
Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma. 254
Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis 222
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 209
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 192
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 183
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 180
AISF position paper on liver disease and pregnancy. 180
Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study 178
Management of Pt1 tumours removed by endoscopy during colorectal cancer screening: Outcome and treatment quality indicators 174
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 173
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 170
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 164
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 157
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 154
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 151
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 144
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 143
Discordant results for IL28B genotyping (rs12979860 vs. rs8099917) and the prediction of rapid viral response in chronic hepatitis C 140
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 139
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 132
Multiple courses of G-CSF in patients with decompensated cirrosi: consistent mobilization of immature cells ex pressing hepatocyte markers and exploratory clinical evaluation. 127
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 122
Hepatitis: PEG-IFN for the treatment of hepatitis D 119
Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations 112
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. 109
IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients 106
Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma 105
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 103
Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency 102
The clinical role of serum epidermal growth factor receptor 3 in hepatitis c virus-infected patients with early hepatocellular carcinoma 100
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 98
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 97
Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology 96
Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF) 95
Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in chronic hepatitis D 93
Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology 93
[Cyclosporin for steroid refractory ulcerative colitis. Results of a study conducted at Turin General Hospital between 1990 and 1997] 92
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 91
Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy 88
Incidence of Type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: results of a controlled follow-up study. 87
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. 86
Addition of Bismuth to the Standard Triple Therapy for Helicobacter Pylori Infection 85
Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen level in the natural history of chronic HBV infection 84
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study 84
Epatocarcinoma: biomarcatori nella prevenzione, diagnosi e cura 83
Type 2 diabetes mellitus and chronic hepatitis C: Which is worse? Results of a long-term retrospective cohort study. 81
A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin 80
DROPLET DIGITAL PCR APPLICATION FOR HEPATITIS DELTA VIREMIA QUANTIFICATION 80
Importance of HLA-B in the sustained virological response in patients with chronic hepatitis C treated with peg-IFN and ribavirin 80
Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in patients with chronic hepatitis D 79
TT virus infection in Italy: prevalence and genotypes in healthy subjects, viral liver diseases and asymptomatic infections by parenterally transmitted viruses. 78
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 76
Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay 75
Chronic HBV related liver disease 74
Epithelioid haemangioendothelioma of the liver: report of a case submitted to orthotopic liver transplantation. 73
Practical out-patient management of autoimmune hepatitis 73
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. 73
Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group. 72
Microarrays analysis for predicting treatment response in patients with chronic hepatitis C: preliminary data 72
Risk of hepatocellular carcinoma development in patients with cirrhosis of viral etiology assessed by protein induced by vitamin k absence or agonist II 72
Gene expression profiles for predicting treatment response in patients with chronic hepatitis C: preliminary analysis 71
Hepatitis B-core related antigen levels during nucleos(t)ide analogues or pegylated-interferon treatment in patients chronically infected with HBV genotype-D 71
Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? 71
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 71
A NOVEL APPROACH FOR HEPATITIS DELTA VIRUS VIREMIA QUANTIFICATION BY DROPLET DIGITAL PCR ASSAY 68
Risk of developing hepatocellular carcinoma in patients with cirrhosis of viral etiology evaluated by the combination of alphafetoprotein, protein induced by vitamin K absence or antagonist-II and glypican-3 68
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 67
RELATIONSHIP OF GENETIC VARIATIONS OF THE GENE CODING FOR THE HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER-1 (HENT1) WITH PROTEIN EXPRESSION AND RESPONSE TO TREATMENT IN CHRONIC HEPATITIS C 67
Immunological and virological markers during pegylated interferon therapy in HDV chronic hepatitis: any predictor of response? 67
Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin 66
Epidemiology and clinical course of hepatitis delta virus infection over 15 years in a liver center in Northern Italy 66
Persistence of autoantibodies against recombinant mitochondrial and nuclear pore proteins after orthotopic liver transplantation for primary biliary cirrhosis. 66
Thymalfasin in the treatment of hepatitis B and C. 65
Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. 63
A deceiving case of paraplegia 63
SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study 63
Assessment of liver fibrosis in the clinical setting: something is changing? 62
Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients. 61
Therapy of chronic hepatitis C: a critical review. 61
Effect of preoperative radiological treatment of hepatocellular carcinoma before liver transplantation: a retrospective study. 61
TREATMENT WITH INTERFERON-alfa2b OF NAIVE NON-CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS C ACCORDING TO VIRAEMIA AND GENOTYPE. RESULTS OF A RANDOMIZED MULTICENTRE STUDY 61
Recurrent Sweet's syndrome in reactivated Crohn's disease. 60
HBV cccDNA evaluation in HBV-core antibody (HBcAb)-positive liver transplant donors 60
Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents 57
Spectral electroencephalogram analysis in hepatic encephalopathy and liver transplantation. 55
CROSS-SECTIONAL AND LONGITUDINAL EVALUATION OF ALPHA-FETOPROTEIN (AFP) AND PROTEIN INDUCED BY VITAMIN K ABSENCE OR ANTAGONIST II (PIVKA-II) IN PATIENTS WITH CIRRHOSIS OF VIRAL ETIOLOGY UNDER SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA (HCC) 55
Peripheral neuropathy after viral eradication with direct-acting antivirals in chronic HCV hepatitis: A prospective study 55
The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease 55
Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment 54
Effect of patient characteristics on hospital costs for cirrhosis: implications for the disease-related group (DRG) reimbursement system. 53
Totale 12.982
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.921
article - articoli 0
book - libri 0
conference - conferenze 8.159
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.080
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019485 0 0 0 0 0 0 0 0 0 164 211 110
2019/20202.567 110 94 102 232 225 428 271 164 223 298 212 208
2020/20211.820 196 134 131 115 180 136 145 85 169 161 126 242
2021/20222.623 146 159 178 200 183 201 225 180 140 186 409 416
2022/20232.683 285 226 70 259 222 632 239 164 267 78 149 92
2023/20241.064 179 204 87 80 80 169 69 105 16 75 0 0
Totale 15.088